Sabra Health Care REIT Sees FY24 Normalized AFFO $1.39-$1.43
Sabra Health Care REIT Sees FY24 Normalized AFFO $1.39-$1.43
2024 GUIDANCE
2024 年指南
Sabra is reiterating 2024 earnings guidance ranges as follows (attributable to common stockholders, per diluted common share):
Sabra重申了2024年的收益指导区间如下（归属于普通股股东，摊薄后的每股普通股）：
- Net Income: $0.53 - $0.57
- FFO: $1.33 - $1.37
- Normalized FFO: $1.34 - $1.38
- AFFO: $1.38 - $1.42
- Normalized AFFO: $1.39 - $1.43
- 净收入：0.53 美元-0.57 美元
- FFO：1.33 美元-1.37 美元
- 标准化 FFO：1.34 美元-1.38 美元
- AFFO：1.38 美元-1.42 美元
- 标准化 AFFO：1.39 美元-1.43 美元
Earnings guidance above assumes no 2024 acquisition or disposition activity.
上述收益指引假设2024年没有收购或处置活动。
Commenting on the first quarter's results, Rick Matros, CEO and Chair, said, "As has been evident for several quarters, Sabra's portfolio continues to grow stronger, whether looking at coverage, occupancy, or NOI. Trailing-twelve-month SNF coverage saw a healthy 0.06x increase sequentially, to 1.79x, when excluding the impact of Provider Relief Funds. Our SHOP portfolio continues to improve, and this quarter's results - which faced a challenging year-over-year comp - are in line with our expectations embedded in guidance. Our balance sheet remains strong and is poised to support future growth.
首席执行官兼董事长里克·马特罗斯在评论第一季度的业绩时表示：“正如几个季度所证明的那样，无论是从承保范围、入住率还是NOI来看，Sabra的投资组合都持续增强。如果不包括提供者救济资金的影响，过去十二个月的SNF覆盖率连续增长了0.06倍，达到1.79倍。我们的SHOP投资组合持续改善，本季度的业绩——同比增长面临挑战——符合我们在指导中提出的预期。我们的资产负债表仍然强劲，有望支持未来的增长。
Although we have no new investments to discuss this quarter, the pipeline has improved and with what we are working on, we expect to announce new investments on our second quarter call."
尽管本季度我们没有新的投资可以讨论，但渠道有所改善，根据我们正在进行的工作，我们预计将在第二季度电话会议上宣布新的投资。”